ConductScience.org, home

Paper575446

Epidemic Rift Valley fever in Egypt: observations of the spectrum of human illness.

Laughlin LW and 4 others. Trans R Soc Trop Med Hyg, 1979. Cited by 241 papers, by iCite.

Cite this record

ConductScience Library. Epidemic Rift Valley fever in Egypt: observations of the spectrum of human illness. Papers, record 575446. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/575446

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Epidemic Rift Valley fever in Egypt: observations of the spectrum of human illness.
PubMed
Journal
Trans R Soc Trop Med Hyg
PubMed
Year
1979
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
241
iCite
Relative citation ratio, by iCite
7.28
iCite
Revised in PubMed
2019-05-09
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Laughlin LWL W
2Meegan JMJ M
3Strausbaugh LJL J
4Morens DMD M
5Watten RHR H

Source PubMed

Download CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Rift Valley FeverMajor topic
Adolescent
Adult
Animals
Child
Child, Preschool
Egypt
Eye Diseases
Female
Hemorrhage
Humans
Jaundice
Male
Meningoencephalitis
Middle Aged

Source PubMed

Download CSV of topics

Cited by128

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 241 citations.

PMIDTitleJournalYearIn PapersSource
42623406Viral and host determinants of arboviral disease severity in African populations: A systematic review with meta-analysis.PLoS Negl Trop Dis2026https://conductscience.org/library/papers/42623406PubMed
42607044Opportunities and challenges for countermeasures against Rift Valley fever virus: A quintessential One Health pathogen.PLoS Negl Trop Dis2026https://conductscience.org/library/papers/42607044PubMed
42043234A Newly Established ELISA for the Surveillance of Rift Valley Fever in Dromedary Camels and Their Owners, Kenya 2018.Viruses2026https://conductscience.org/library/papers/42043234PubMed
41961907Epidemiological and molecular characterization of Rift Valley fever outbreak in livestock in Burundi, May - November 2022.PLoS Negl Trop Dis2026https://conductscience.org/library/papers/41961907PubMed
41902294In Vitro and In Vivo Models for Drug Development Against Two Hemorrhagic Hareavirales: Rift Valley Fever and Crimean Congo Hemorrhagic Fever Viruses.Viruses2026https://conductscience.org/library/papers/41902294PubMed
41568981Rift Valley fever virus activates multiple cell death pathways in neurons.J Virol2026https://conductscience.org/library/papers/41568981PubMed
40715124Maternal vaccination with live-attenuated Rift Valley fever virus protects offspring via immune transfer.NPJ Vaccines2025https://conductscience.org/library/papers/40715124PubMed
40703920Research trends in Rift Valley fever virus: a bibliometric analysis from 1936 to 2024.Front Vet Sci2025https://conductscience.org/library/papers/40703920PubMed
40630111The public health threat of emerging phenuiviruses.One Health2025https://conductscience.org/library/papers/40630111PubMed
39928032Rift Valley Fever Virus Infectivity in Milk Stored at a Wide Range of Temperatures.J Infect Dis2025https://conductscience.org/library/papers/39928032PubMed
39452727A Review of Nonhuman Primate Models of Rift Valley Fever Virus Infection: Progress, Challenge Strains, and Future Directions.Pathogens2024https://conductscience.org/library/papers/39452727PubMed
39345143Rift Valley fever virus is able to cross the human blood-brain barrier in vitro by direct infection with no deleterious effects.J Virol2024https://conductscience.org/library/papers/39345143PubMed
39159263The Rift Valley fever (RVF) vaccine candidate 40Fp8 shows an extreme attenuation in IFNARKO mice following intranasal inoculation.PLoS Negl Trop Dis2024https://conductscience.org/library/papers/39159263PubMed
39088277Potent neutralizing human monoclonal antibodies protect from Rift Valley fever encephalitis.JCI Insight2024https://conductscience.org/library/papers/39088277PubMed
39057809Monoclonal Antibodies for Rift Valley Fever Virus Nucleocapsid: Application in IgG/IgM ELISA for Sero-Diagnosis.Pathogens2024https://conductscience.org/library/papers/39057809PubMed
39039428Laboratory Animal Models for Rift Valley Fever Virus Disease.Methods Mol Biol2024https://conductscience.org/library/papers/39039428PubMed
39039413Making Rift Valley Fever Viral Particles Fluorescent.Methods Mol Biol2024https://conductscience.org/library/papers/39039413PubMed
39039406Analysis of Negative-Strand RNA Viruses by RT-qPCR: Rift Valley Fever Virus and Toscana Virus.Methods Mol Biol2024https://conductscience.org/library/papers/39039406PubMed
38935789The lipopeptide Pam3CSK4 inhibits Rift Valley fever virus infection and protects from encephalitis.PLoS Pathog2024https://conductscience.org/library/papers/38935789PubMed
38635867Rift Valley Fever Virus Encephalitis: Viral and Host Determinants of Pathogenesis.Annu Rev Virol2024https://conductscience.org/library/papers/38635867PubMed

See all 128 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/575446

GET https://conductscience.org/api/papers/v1/575446/cited_by?page=2